Regeneron Pharmaceuticals, Inc. $REGN Position Increased by Sterling Capital Management LLC

Sterling Capital Management LLC raised its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 59.3% during the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 15,957 shares of the biopharmaceutical company’s stock after acquiring an additional 5,943 shares during the quarter. Sterling Capital Management LLC’s holdings in Regeneron Pharmaceuticals were worth $12,100,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the business. BlackRock Inc. bought a new stake in Regeneron Pharmaceuticals during the second quarter valued at approximately $5,682,636,000. State Street Corp grew its holdings in Regeneron Pharmaceuticals by 3.6% during the second quarter. State Street Corp now owns 4,834,688 shares of the biopharmaceutical company’s stock valued at $3,014,621,000 after purchasing an additional 170,210 shares during the period. Bank of America Corp DE raised its stake in shares of Regeneron Pharmaceuticals by 8.5% in the second quarter. Bank of America Corp DE now owns 1,291,053 shares of the biopharmaceutical company’s stock worth $805,023,000 after buying an additional 101,469 shares during the period. Amundi increased its holdings in Regeneron Pharmaceuticals by 0.4% in the 2nd quarter. Amundi now owns 1,013,540 shares of the biopharmaceutical company’s stock worth $631,983,000 after acquiring an additional 3,742 shares in the last quarter. Finally, Legal & General Group Plc purchased a new position in Regeneron Pharmaceuticals during the second quarter valued at approximately $473,872,000. Institutional investors own 83.31% of the company’s stock.

Insider Transactions at Regeneron Pharmaceuticals

In related news, Director Huda Zoghbi sold 800 shares of the stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $800.00, for a total transaction of $640,000.00. Following the transaction, the director owned 1,703 shares of the company’s stock, valued at approximately $1,362,400. This represents a 31.96% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Andrew Murphy sold 4,147 shares of the firm’s stock in a transaction that occurred on Wednesday, October 14th. The shares were sold at an average price of $772.70, for a total transaction of $3,204,386.90. Following the completion of the transaction, the insider directly owned 47,833 shares of the company’s stock, valued at approximately $36,960,559.10. The trade was a 7.98% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 8,093 shares of company stock worth $6,506,845 in the last 90 days. Insiders own 6.97% of the company’s stock.

Regeneron Pharmaceuticals News Roundup

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: TD Cowen raised its price target to $980 from $960 while maintaining a positive view of Regeneron, signaling potential upside from current levels. TD Cowen raises target for Regeneron stock
• Positive Sentiment: Analysts and investors continue to point to Regeneron’s growth potential, including strong Dupixent performance and positive Phase 3 OPTIMA results for investigational pasatru in fibrodysplasia ossificans progressiva. The company is also working to build a broader global oncology business. Regeneron growth potential analysis
• Neutral Sentiment: Regeneron is scheduled to report quarterly results next week. Analysts expect earnings to grow, but the company reportedly lacks the typical combination of estimate revisions and other indicators associated with a likely earnings beat, creating uncertainty ahead of the release. Regeneron earnings expectations
• Neutral Sentiment: Recent coverage describes REGN as a relatively steady stock and notes that it gained in the prior session, although it lagged some competitors. This provides limited new information about the company’s fundamentals. Regeneron stock performance versus competitors
• Negative Sentiment: Valuation-related commentary asks whether Regeneron is priced too highly relative to pharmaceutical peers, which could limit near-term upside and encourage profit-taking ahead of earnings. Regeneron valuation versus rivals

Regeneron Pharmaceuticals Stock Performance

NASDAQ REGN traded down $14.07 on Friday, hitting $805.02. 527,731 shares of the company’s stock traded hands, compared to its average volume of 705,231. The company has a current ratio of 3.34, a quick ratio of 2.78 and a debt-to-equity ratio of 0.06. Regeneron Pharmaceuticals, Inc. has a 1-year low of $575.93 and a 1-year high of $859.34. The firm’s 50-day moving average price is $791.86 and its two-hundred day moving average price is $723.16. The firm has a market capitalization of $82.88 billion, a PE ratio of 19.90, a P/E/G ratio of 1.38 and a beta of 0.16.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share for the quarter, beating the consensus estimate of $10.16 by $4.13. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The company had revenue of $4.29 billion for the quarter, compared to analyst estimates of $3.82 billion. During the same period in the previous year, the business posted $12.81 EPS. Regeneron Pharmaceuticals’s revenue was up 16.7% on a year-over-year basis. As a group, analysts expect that Regeneron Pharmaceuticals, Inc. will post 49.10 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, August 31st. Shareholders of record on Tuesday, August 18th were given a $0.94 dividend. The ex-dividend date of this dividend was Tuesday, August 18th. This represents a $3.76 dividend on an annualized basis and a yield of 0.5%. Regeneron Pharmaceuticals’s payout ratio is presently 9.29%.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on REGN shares. Wall Street Zen upgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Sunday, September 20th. Robert W. Baird upped their price target on Regeneron Pharmaceuticals from $742.00 to $761.00 and gave the stock a “neutral” rating in a research note on Friday, July 31st. TD Cowen lifted their price objective on shares of Regeneron Pharmaceuticals from $960.00 to $980.00 and gave the company a “buy” rating in a research report on Wednesday. HSBC upped their target price on shares of Regeneron Pharmaceuticals from $800.00 to $920.00 and gave the stock a “buy” rating in a research report on Thursday, September 10th. Finally, Zacks Research raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Monday, September 28th. One analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and eight have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $846.28.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.